Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peroxisome proliferator activity in the liver primarily refers to the function of peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptor proteins that act as transcription factors regulating gene expression in response to ligands such as fatty acids and their derivatives. The PPAR family consists of three main subtypes: PPARα, PPARβ/δ, and PPARγ. These receptors play crucial roles in lipid and glucose metabolism, inflammation, cell proliferation, and differentiation within the liver. Alterations in hepatic PPAR activity are implicated in several diseases, including NAFLD, metabolic syndrome, and diabetes. Activation or inhibition of hepatic PPARs is a therapeutic strategy for metabolic diseases; however, exogenous activation can have side effects limiting clinical use.
Ligand-dependent activation of PPARs, leading to heterodimerization with retinoid X receptors (RXRs) and binding to peroxisome proliferator response elements (PPREs) on DNA, modulating gene expression.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peroxisome Proliferator-Activated Receptors (Hepatic) (PPARs (Hepatic)).